Prime Medicine Inc 's (PRME) Outlook - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
Prime Medicine Inc   (NASDAQ: PRME)
 



  Prime Medicine Inc Outlook

On April 23 2024 the Prime Medicine Inc provided following guidance

Prime Medicine Inc. has recently announced that they will be presenting new preclinical data at upcoming scientific meetings to showcase the broad potential of their Prime Editing technology. This includes data for PM359, which demonstrates the ability of Prime Editors to efficiently, reproducibly, and durably correct the causative mutation of CGD (Chronic Granulomatous Disease). This development is a significant milestone for the company as they are on track to enter clinical development in 2024, with initial data expected to be released in 2025.

In addition to this exciting announcement, Prime Medicine Co-Founder, David Liu, Ph.D., has been awarded the ASGCT Outstanding Achievement Award, highlighting his contributions to the field of gene editing. This recognition further solidifies Prime Medicine's position as a leader in the field of genetic medicine and reaffirms their commitment to developing innovative therapies that have the potential to transform patient care.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.